175 related articles for article (PubMed ID: 38111569)
1. The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis.
Káposztás E; Balogh L; Mócsai A; Kemecsei É; Jakus Z; Németh T
Front Immunol; 2023; 14():1279155. PubMed ID: 38111569
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
3. Lineage-Specific Analysis of Syk Function in Autoantibody-Induced Arthritis.
Németh T; Futosi K; Szilveszter K; Vilinovszki O; Kiss-Pápai L; Mócsai A
Front Immunol; 2018; 9():555. PubMed ID: 29616043
[TBL] [Abstract][Full Text] [Related]
4. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.
Cho S; Jang E; Yoon T; Hwang H; Youn J
Clin Exp Immunol; 2023 Mar; 211(1):31-45. PubMed ID: 36346114
[TBL] [Abstract][Full Text] [Related]
5. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
[TBL] [Abstract][Full Text] [Related]
6. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
[TBL] [Abstract][Full Text] [Related]
8. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
9. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis.
Jakus Z; Simon E; Balázs B; Mócsai A
Arthritis Rheum; 2010 Jul; 62(7):1899-910. PubMed ID: 20201079
[TBL] [Abstract][Full Text] [Related]
10. The Syk Inhibitor Entospletinib Abolishes Dermal-Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid.
Vikár S; Szilveszter KP; Koszorú K; Sárdy M; Mócsai A
J Invest Dermatol; 2024 Jan; ():. PubMed ID: 38296021
[TBL] [Abstract][Full Text] [Related]
11. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases.
Zhou Y; Zhang Y; Yu W; Qin Y; He H; Dai F; Wang Y; Zhu F; Zhou G
Immun Inflamm Dis; 2023 Jul; 11(7):e934. PubMed ID: 37506139
[TBL] [Abstract][Full Text] [Related]
13. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
14. Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis.
Ozaki N; Suzuki S; Ishida M; Harada Y; Tanaka K; Sato Y; Kono T; Kubo M; Kitamura D; Encinas J; Hara H; Yoshida H
Int Immunol; 2012 Sep; 24(9):539-50. PubMed ID: 22914861
[TBL] [Abstract][Full Text] [Related]
15. [Research Advance on the Role of Spleen Tyrosine Kinase Inhibitors in Hematologic Malignancies].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):1054-1058. PubMed ID: 32552981
[TBL] [Abstract][Full Text] [Related]
16. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors.
Lee SJ; Choi JS; Bong SM; Hwang HJ; Lee J; Song HJ; Lee J; Kim JH; Koh JS; Lee BI
Mol Cells; 2018 Jun; 41(6):545-552. PubMed ID: 29890824
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
19. Syk inhibitors in clinical development for hematological malignancies.
Liu D; Mamorska-Dyga A
J Hematol Oncol; 2017 Jul; 10(1):145. PubMed ID: 28754125
[TBL] [Abstract][Full Text] [Related]
20. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
Life Sci; 2017 Dec; 191():166-174. PubMed ID: 29056373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
